Daniel K. Spiegelman Elected to Board of Directors of Omeros Seattle, Washington

Daniel K. Spiegelman Elected to Board of Directors of Omeros

Seattle, Washington December 09, 2009 Omeros Corporation today announced that its Board of

Directors has elected Daniel K. Spiegelman to serve on the Company s Board. Mr. Spiegelman has also

been appointed to serve as Chairman of the Audit Committee.

We are very pleased to welcome Dan to our Board and look forward to working with him, stated

Gregory Demopulos, M.D., Chairman and CEO of Omeros. Dan brings a substantial depth and breadth of

financial experience in public biotech companies. He will be a valuable asset to Omeros as we

prepare to bring our products to market.

I am excited to be joining Omeros Board, stated Daniel Spiegelman. The strength of the

Company s management team and pipeline provide significant and multiple opportunities to advance

science and improve the lives of patients. I look forward to contributing to the Company s

Mr. Spiegelman has over 25 years of executive management, finance and operations experience. He was

senior vice president and chief financial officer at CV Therapeutics prior to and during its

acquisition by Gilead earlier this year. Prior to that, he was employed by Genentech, where he

served as Treasurer and held a number of other senior financial positions. Mr. Spiegelman also

serves on the boards of directors and chairs the audit committees of Affymax, Cyclacel

Pharmaceuticals and Oncothyreon, all publicly traded biopharmaceutical companies. He earned his

M.B.A. from the Stanford Graduate School of Business and his B.A. in economics from Stanford

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering,

developing and commercializing products focused on inflammation and disorders of the central

nervous system. Omeros most clinically advanced product candidates are derived from its

proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing

arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has

four ongoing PharmacoSurgery clinical development programs, and its lead product candidate,

OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to

improve postoperative joint function and reduce postoperative pain. Omeros is also building a

diverse pipeline of preclinical programs targeting inflammation and central nervous system

For more information on Omeros, visit the Company s website at www.omeros.com

Forward-Looking Statements

This press release contains forward-looking statements as defined within the Private Securities

Litigation Reform Act of 1995, which are subject to the safe harbor created by those sections.

These statements include, but are not limited to, statements regarding the ability of the Company s

management team and pipeline to advance science and improve the lives of patients. Forward-looking

statements are based on management s beliefs and assumptions and on information available to

management only as of the date of this press release. Omeros actual results could differ

materially from those anticipated in these forward-looking statements for many reasons, including,

without limitation, the risks, uncertainties and other factors described under the heading Risk

Factors in the Company s Quarterly Report on Form 10-Q filed with the Securities and Exchange

Commission on November 19, 2009. Given these risks, uncertainties and other factors, you should not

place undue reliance on these forward-looking statements, and the Company assumes no obligation to

update these forward-looking statements publicly, even if new information becomes available in the